APA (7th ed.) Citation

Haynesworth, A., Yeh, K., Lee, H. H., Kirkpatrick, M., Boland, B. S., Syal, G., . . . Singh, S. (2025). Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis. Alimentary Pharmacology & Therapeutics, 61(4), 693. https://doi.org/10.1111/apt.18441

Chicago Style (17th ed.) Citation

Haynesworth, Austin, Kuan‐Hung Yeh, Han Hee Lee, Melissa Kirkpatrick, Brigid S. Boland, Gaurav Syal, Ronghui Xu, and Siddharth Singh. "Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis." Alimentary Pharmacology & Therapeutics 61, no. 4 (2025): 693. https://doi.org/10.1111/apt.18441.

MLA (9th ed.) Citation

Haynesworth, Austin, et al. "Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis." Alimentary Pharmacology & Therapeutics, vol. 61, no. 4, 2025, p. 693, https://doi.org/10.1111/apt.18441.